COO

Business Profile & Competitive Position

The Cooper Companies, Inc. operates in the Healthcare sector, specifically the Medical – Instruments & Supplies industry. Its business is split between two segments. CooperVision develops, manufactures and markets disposable, two-week and monthly contact lenses and specialized eyecare products, including silicone hydrogel lenses, orthokeratology and scleral lenses, plus the MiSight 1 day myopia-management lens. CooperSurgical sells more than 600 products and services focused on fertility and women’s health, covering gynecology, obstetrics, contraception, labor and delivery, IVF support, donor gametes, cryopreservation, cord blood/tissue storage and genomic services.

The financial signatures of the franchise are a 13.5% net margin and a 6.9% return on equity. The net margin is solidly double-digit, which is consistent with a medical-device business that derives recurring revenue from consumables such as contact lenses and fertility-oriented supplies. The ROE, however, is comfortably below the double-digit levels typical of highly capital-light compounders, implying a heavier asset base, meaningful reinvestment needs, or both. On balance, the numbers point to a moderate competitive position: the company appears to have pricing power and regulatory differentiation—MiSight 1 day is approved by the FDA, China’s NMPA and Japan’s MHLW to slow myopia progression in age-appropriate children—but its returns suggest it is not a wide-moat, low-capital business. Product breadth, global distribution and regulatory approvals are the likely sources of whatever moat exists.

Financial Posture

At the current snapshot, The Cooper Companies carries a market capitalization of $10.5 billion, trades at a trailing P/E of 18.4, and reports a net margin of 13.5% and ROE of 6.9%. The stock’s beta is 0.82, which is defensive relative to the broad market, and the current price is $53.91. For added technical context, the 50-day EMA sits at $69.99 and the 14-day RSI is 14.5, both of which corroborate that the shares have sold off sharply.

An 18.4x P/E combined with a 13.5% net margin produces an earnings yield of about 5.4%. That multiple sits below the valuation of many faster-growing medical-device peers, but it aligns with the company’s below-average ROE and the current risk-off narrative around U.S. channel inventories. The 0.82 beta implies the stock historically moves less than the market, though recent price action suggests company-specific news can easily overwhelm that tendency.

Strategic Priorities & Outlook

The company’s most recent 10-K filing outlines a straightforward set of priorities. On the CooperVision side, management is focused on driving global penetration of recently introduced products, expanding in existing and emerging markets, and increasing investment in distribution and packaging capabilities to support growth and service levels. CooperVision is also investing to develop the myopia-management market by educating eye-care practitioners, patients and families.

On the CooperSurgical side, the strategic direction centers on continuing to invest in the business, including through strategic transactions, to expand its integrated solutions model within fertility and women’s health. Operational scale is meaningful: products are sold in more than 130 countries and reach over fifty million lives each year, and the company employs approximately 500 people in research and development across both segments.

Macro & Geopolitical Exposure

Because the company sits in the Medical – Instruments & Supplies industry, its exposures map naturally onto the healthcare ecosystem. Regulatory risk is the most prominent: contact lenses, fertility devices and related consumables require approvals from bodies such as the FDA, NMPA and MHLW, and any changes to labeling, reimbursement or compliance standards can move revenue and margins.

Global manufacturing and distribution create currency-translation and supply-chain exposure. Medical-device components rely on plastics, packaging and precision manufacturing, so input-cost volatility, freight rates and trade policy are relevant. Demographics provide potential tailwinds: rising myopia rates support CooperVision’s myopia-management portfolio, while delayed childbearing and increased uptake of fertility treatments support CooperSurgical. Tariffs or trade restrictions on medical goods, however, could offset some of that demand benefit.

Recent Developments

The most recent catalyst is a September 12, 2026, globenewswire.com headline from HBSS stating that The Cooper Companies “Scrutinized Over U.S. Channel Inventory Reductions Driving Stock Sharply Lower.” That narrative aligns with the price collapse to $53.91 and the 14.5 RSI reading, and it underscores how a beat-and-raise earnings print can still be overwhelmed by concerns about distributor destocking.

On September 11, 2026, both prnewswire.com and businesswire.com carried law-firm announcements: Levi & Korsinsky notified investors of a pending investigation into Cooper Companies, and the Law Offices of Howard G. Smith invited shareholders who lost money to contact the firm about a securities-fraud investigation. These releases are typical after steep stock drops and do not constitute findings of wrongdoing, but they add headline and reputational risk.

Also on September 11, 2026, fool.com published a headline about Nike COO Alagirisamy Venkatesh selling 3,671 shares. That item carries the “COO” ticker tag but relates to Nike’s chief operating officer, not The Cooper Companies; it is useful only as an example of ticker-level noise that can appear in news feeds.

Earnings Behavior & Post-Earnings Drift

Over the last eight reported quarters, Cooper Companies has beaten consensus earnings estimates 8 out of 8 times, or 100%, with an average earnings surprise of 4.2%. The average 5-day price move in the trading sessions after those reports is a positive 1.54%, classified as an “up” drift direction.

That top-line pattern conceals significant quarter-to-quarter volatility. On September 9, 2026, the company reported actual EPS of $1.15 versus an estimate of $1.12, a 2.7% beat, yet the stock fell 14.67% the next day and recorded a 0% change over the following five days. By contrast, the June 4, 2026 quarter produced a 10% beat ($1.21 vs. $1.10) and a next-day gain of 8.58%, extending to 8.85% over five days. The March 5, 2026 quarter was also a beat, 6.8% above estimate ($1.10 vs. $1.03), but the stock fell 4.55% the next day and 10.82% over the next five sessions. The December 4, 2025 quarter, a 3.6% beat ($1.15 vs. $1.11), generated a 5.67% next-day rally and a 6.59% five-day gain.

The takeaway is that beating the consensus is not enough to guarantee a positive reaction; the market’s focus is on guidance, channel-inventory commentary and segment momentum. The next scheduled report is December 3, 2026, after the close, with a consensus EPS estimate of $1.11.

For a deeper dive into how institutional analysts are currently modeling Cooper Companies’ recovery path, channel-inventory trajectory and valuation, readers should review the full institutional verdict on the stock.